Zilucoplan

The MGFA Food Support Program is providing premade, packaged meals delivered directly to the homes of patients with MG.  Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems swallowing, issues that can make mealtimes especially difficult for patients with MG.Households affected by MG often struggle to prepare regular, healthy meals because the disease can make cooking and eating difficult for the family member living with MG, according to the Myasthenia Gravis Foundation of America. Those challenges can be even greater for families living in areas considered nutrition deserts or facing food insecurity, increasing the risk of poor health outcomes.To help, UCB is partnering with the Myasthenia Gravis Foundation of America and meal-prep company Factor Meals to ease the burden of making nutritious meals.Known as the MGFA Food Support Program, the collaboration provides premade, packaged meals delivered directly to the homes of patients with MG. The aim is to have MG patients apply over the next month, with deliveries beginning in June. The foundation said it plans to support 250 families in 2026 and will close enrollment once that target is reached.“If we want to support improving health outcomes, we have to address the barriers that exist outside of the healthcare setting,” said Aprill Lane, U.S. advocacy lead for rare disease at UCB, in an April 20 release.“Our collaboration with MGFA is an example of how we can lead and partner differently by co-creating programs that support the whole person not just the diagnosis.” UCB markets Rystiggo and Zilbrysq for certain patients with MG, generating €332 million and €217 million, respectively, in 2025 sales.

UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)1 UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026 April 13, 2026 -- UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The studies evaluated the effectiveness of a ZLP- AI as a potential new alternative administration option, and the bioequivalence of ZLP-AI relative to ZLP-PFS. ZLP-AI is an investigational administration option for the treatment of gMG in adult patients who are anti-AChR antibody positive and the presentation is currently not approved in the U.S. DV0013 was a Phase 3b open-label, multicenter study in adult patients with gMG self-administering zilucoplan via auto-injector once daily.1 DV0012 was a Phase 1, open-label, single-center, two-period crossover study in healthy adult volunteers to establish bioequivalence of zilucoplan delivered via an auto-injector pen compared with a pre-filled syringe.1 "While symptom control is of course essential, successfully treating gMG should go beyond symptom management and consider tailored therapies that align with a patient's needs, lifestyle and quality-of-life goals," said Omar Sinno, MD, US Medical Strategy Lead, US Rare Disease. UCB will also present five additional studies and data analyses, further highlighting UCB's ongoing commitment to improving outcomes for people living with gMG including: Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post Hoc Analysis of Final Pooled Phase 3 Data: An analysis evaluated the response to rozanolixizumab over multiple treatment cycles in adult patients with gMG, based on their Cycle 1 response.2 Sustained Minimal Symptom Expression in Generalized Myasthenia Gravis: A 120-Week Post Hoc Analysis of RAISE-XT: A post hoc analysis assessed the durability of minimal symptom expression (MSE) response during treatment with zilucoplan in patients with gMG.3 Treatment Goals in Myasthenia Gravis: Expert Consensus Recommendations. Using the RAND/UCLA Appropriateness Method: Seventeen myasthenia gravis experts from North America, Europe and Asia reached consensus on 21 recommendations to define and operationalize treatment goals for patients with MG. Recommendations emphasize the importance of patient engagement and education, reassessing and changing treatment to achieve goals and care coordination with other specialists.4 Treatment Characteristics and Healthcare Resource Utilization Among Adult Patients With Generalized Myasthenia Gravis Initiating Rozanolixizumab in the United States: This real-world, retrospective, non-interventional cohort study of adult patients (N=719) receiving rozanolixizumab in the US evaluated treatment patterns and healthcare resource utilization (HCRU).5 Missed Opportunities for Pharmacist Intervention Among Medicare Fee-for-Service Beneficiaries with Myasthenia Gravis: A Real-World Claims Analysis.6 "At UCB, our approach to rare disease goes beyond developing effective medicines; it's about improving overall experience and outcome for patients," said Kimberly Moran, PhD, SVP & Head, US Rare Disease. "By offering innovative solutions designed around patient needs and preferences, we continue in our mission to help people living with rare diseases better manage their condition through targeted therapies." gMG is a rare neuromuscular autoimmune disease that has a global prevalence of 150–350 cases per 1 million people.7 People living with gMG can experience a variety of symptoms, including severe muscle weakness that can result in double vision, drooping eyelids, difficulty with swallowing, chewing and talking, as well as life-threatening weakness of the muscles of respiration. In gMG, pathogenic autoantibodies can impair synaptic transmission at the neuromuscular junction (NMJ) by targeting specific proteins on the post-synaptic membrane. This disrupts the ability of the nerves to stimulate the skeletal muscle and results in a weaker contraction. gMG can occur in any race, gender or age. UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). References: Petrulis et al. DV0012 and DV0013 Study Teams. Bioequivalence and effectiveness of auto–injector–delivered, self–administered zilucoplan compared with pre–filled syringe. Abstract presented at the American Academy of Neurology Annual Meeting, April 2026. Pascuzzi et al. Response to rozanolixizumab across treatment cycles in patients with generalized myasthenia gravis: A post hoc analysis of final pooled phase 3 data. Abstract presented at the American Academy of Neurology Annual Meeting, April 2026. Howard et al. RAISE–XT Study Team. Sustained minimal symptom expression in generalized myasthenia gravis: A 120–week post hoc analysis of RAISE–XT. Abstract presented at the American Academy of Neurology Annual Meeting, April 2026. Narayanaswami et al. Treatment goals in myasthenia gravis: Expert consensus recommendations using the RAND/UCLA Appropriateness Method. Abstract presented at the American Academy of Neurology Annual Meeting, April 2026. Kumar et al., Treatment characteristics and healthcare resource utilization among patients with generalized myasthenia gravis initiating rozanolixizumab in the United States. Abstract presented at the American Academy of Neurology Annual Meeting, April 2026. Thompson et al. Missed opportunities for pharmacist intervention among Medicare fee–for–service beneficiaries with myasthenia gravis: a real–world claims analysis. Abstract presented at: American Academy of Neurology Annual Meeting, April 2026. Rodrigues, E., Umeh, E., Aishwarya, Navaratnarajah, N., Cole, A., & Moy, K. (2024). Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis. Muscle & nerve, 69(2), 166–171. The content above comes from the network. if any infringement, please contact us to modify.